Eva Lucille Feldman, MD, PhD

Dr. Feldman is the director of the NeuroNetwork for Emerging Therapies at Michigan Medicine and the ALS Center of Excellence at Michigan Medicine. The latter includes the Pranger ALS Clinic, one of the top multidisciplinary clinics caring for those suffering from amyotrophic lateral sclerosis (ALS). She serves as the University of Michigan James W. Albers Distinguished University Professor and the Russell N. DeJong Professor of Neurology at Michigan Medicine. Dr. Feldman is one of the world’s leading authorities on neurodegenerative disease.

Dr. Feldman is a compassionate and dedicated physician who cares deeply about her patients. She has been recognized for her clinical excellence by numerous organizations and is annually named as one of the “Best Doctors in America.” Her forward-thinking, collaborative, multidisciplinary approach has transformed how neurodegenerative diseases are diagnosed, treated, and prevented.

Dr. Feldman has made significant contributions to biomedical research and clinical care in many critical areas of neurodegenerative disease. She has authored over 530 peer-reviewed publications, 74 book chapters, and 5 books on the pathology, diagnosis, and treatment of neurological diseases. Dr. Feldman has been continuously funded by the NIH since 1989 and is currently the principal or co-investigator of numerous clinical trials and grants. She has received numerous awards and honors throughout her remarkable career, including the University of Michigan’s Early Distinguished Career Award, the Distinguished Faculty Achievement Award, and the Distinguished Alumnus Achievement Award. She was also the first woman in 25 years to receive the Robert S. Schwab Award from the American Clinical Neurophysiology Society. In 2022, Dr. Feldman was awarded the University of Michigan Distinguished Professorship, the highest faculty honor at University of Michigan.

Dr. Feldman is actively committed to and involved in professional service. She served as President of the Peripheral Nerve Society from 2007-2009 and President of the American Neurological Association (ANA) from 2011-2013. Dr. Feldman is an elected member of the National Academy of Medicine (NAM) and Association of American Physicians, and a Fellow of the American Association for the Advancement of Science. Dr. Feldman is the Editor of the Contemporary Neurology Series and also serves on a number of editorial boards for leading scientific journals, including The Lancet Neurology, Nature Reviews Neurology, JAMA Neurology and Journal of Neurology, Neurosurgery and Psychiatry.

University of Michigan Health participates with most health insurance plans.

Dr. Feldman established the The NeuroNetwork for Emerging Therapies in 2000 where she directs a team of over 40 scientists, technicians and administrative staff who are dedicated to understanding and treating neurodegenerative disease. Her work focuses on three major themes:

1. Understanding how metabolic dysfunction, such as diabetes and obesity, drives neurologic complications and impacts brain health.

2. Determining the underly mechanisms and treatment strategies for neurological disorders, including ALS, Alzheimer’s disease, and neuropathy.

3. Identifying risk factors, such as environmental toxins, associated with neurological disorders and advocating for cleaner and safer environments as a way to treat disease.

4. Developing stem cell therapies as a treatment strategy for neurological disease.

For more information on Dr. Feldman’s research and career, please visit:

NeuroNetwork for Emerging Therapies

Wikipedia

Michigan Research Experts

Selected publications:

• Reynolds, E. L., (…) Pennathur, S., Feldman, E. L., & Callaghan, B. C. (2023). The effect of surgical weight loss on diabetes complications in individuals with class II/III obesity. Diabetologia, 10.1007/s00125-023-05899-3.
• Henn, R. E., (…) Savelieff, M. G., Hur, J., & Feldman, E. L. (2023). Single-cell RNA sequencing identifies hippocampal microglial dysregulation in diet-induced obesity. iScience, 26(3), 106164. Goutman, S. A., (…) Karnovsky, A., Mukherjee, B., & Feldman, E. L. (2023). Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles. Muscle & nerve, 67(3), 208–216.
• McGinley, L. M., (…) Reynolds, E. L., Murphy, G. G., & Feldman, E. L. (2022). Monoclonal antibody-mediated immunosuppression enables long-term survival of transplanted human neural stem cells in mouse brain. Clinical and translational medicine, 12(9), e1046.
• Afshinnia, F., (…) Callaghan, B. C., Pennathur, S., & Feldman, E. L. (2022). Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes. Annals of clinical and translational neurology, 9(9), 1392–1404.
• Goutman, S. A., (…) Mukherjee, B., Feldman, E. L., & Batterman, S. A. (2022). Associations of self-reported occupational exposures and settings to ALS: a case-control study. International archives of occupational and environmental health, 95(7), 1567–1586.
• Goutman, S. A., (…) Patil, P. G., Sakowski, S. A., & Feldman, E. L. (2018). Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Annals of clinical and translational neurology, 5(6), 730–740.
• Callaghan, B. C., (…) Pop-Busui, R., Feldman, E. L., & Ji, L. (2018). Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Annals of clinical and translational neurology, 5(4), 397–405.